Fulcrum Asset Management LLP Purchases 79,087 Shares of Cencora, Inc. $COR

Fulcrum Asset Management LLP grew its holdings in Cencora, Inc. (NYSE:COR) by 152.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 130,835 shares of the company’s stock after purchasing an additional 79,087 shares during the quarter. Cencora comprises 1.8% of Fulcrum Asset Management LLP’s portfolio, making the stock its 5th biggest holding. Fulcrum Asset Management LLP owned approximately 0.07% of Cencora worth $40,245,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Cencora in the 2nd quarter valued at approximately $5,154,136,000. Bank of America Corp DE grew its holdings in shares of Cencora by 6.9% during the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after purchasing an additional 267,318 shares in the last quarter. Amundi grew its holdings in shares of Cencora by 43.5% during the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after purchasing an additional 676,066 shares in the last quarter. Carmignac Gestion increased its position in shares of Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after purchasing an additional 646,112 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Cencora during the second quarter valued at approximately $483,772,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.38% of the company’s stock.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat quarterly expectations, reporting EPS of $4.66 versus estimates of $4.58 and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year. The company also issued a stronger fiscal 2027 earnings outlook, reinforcing expectations for continued growth. Cencora stock enters fiscal 2027 with stronger earnings outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 from $388 and maintained an “outperform” rating, signaling confidence in potential upside.
• Positive Sentiment: Cencora raised its dividend, adding to its appeal for income-focused investors amid market uncertainty. Stocks that hiked dividends
• Neutral Sentiment: The company is realigning its corporate structure. The available report headline does not specify the changes or their expected financial impact. Cencora realigning corporate structure
• Negative Sentiment: Despite Cencora’s earnings beat, shares came under pressure after rival Cardinal Health reported results, prompting concern about relative performance and contributing to a short-term pullback. Cencora drops while rival Cardinal Health posts a beat

Cencora Stock Performance

Cencora stock opened at $333.38 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.59 and a debt-to-equity ratio of 3.01. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The company has a market cap of $63.62 billion, a PE ratio of 18.60, a PEG ratio of 1.72 and a beta of 0.58. The company’s 50-day moving average is $325.07 and its two-hundred day moving average is $317.28.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.08. The company had revenue of $88.35 billion for the quarter, compared to analyst estimates of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.84 EPS. Equities analysts anticipate that Cencora, Inc. will post 19.58 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be given a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, November 13th. This is a positive change from Cencora’s previous quarterly dividend of $0.60. Cencora’s dividend payout ratio is presently 14.73%.

Analysts Set New Price Targets

Several research analysts recently issued reports on COR shares. Robert W. Baird increased their price target on shares of Cencora from $373.00 to $375.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. UBS Group reduced their target price on Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, October 16th. Argus increased their price target on Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Weiss Ratings raised Cencora from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, October 6th. Finally, Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $368.73.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.